2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 291-292
Technology and Procedures, Omics Technologies, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Immunotherapy, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, White Blood Cell Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

23 A multicenter, open-label phase 1b dose-exploration and expansion study of oric-1940, a RIPK1 inhibitor, combined with Etoposide–Dexamethasone in refractory adult HLH

Luocheng Zhang, Yang Dai, PhD2, Xushu Zhong3, Shengyong Yang4, Yushuang Xiao5, Jia Miao6, Xu Sun, PhD7, Fang Xu8, Xi Zhang, MD9, Xuefeng He10, Rui Huang11, Shuangnian Xu12, Xuedan You13, Yijun Wu, MD14, Ailin Zhao, PhD15, Ting Niu16
1 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
2 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
3 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
4 Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, Chengdu, China
5 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
6 Clinical Trial Center, West China Hospital, Sichuan University., Chengdu, China
7 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
8 Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China., Mianyang, China
9 Department of Hematology, The Second Affiliated Hospital of Army Medical University., Chongqing, China
10 Department of Hematology, The First Affiliated Hospital of Soochow University., Suzhou, China
11 Department of Hematology, Zhujiang Hospital of Southern Medical University., Guangzhou, China
12 Department of Hematology, The First Affiliated Hospital of Army Medical University., Chongqing, China
13 Chengdu Pharscin Origiant Pharmaceutical Co., Ltd. (a member of Pharscin Innobio)., Chengdu, China
14 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
15 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
16 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Background: Adult hemophagocytic lymphohistiocytosis (HLH), particularly Epstein–Barr virus (EBV)- and lymphoma-associated HLH, is a rapidly progressive hyperinflammatory disorder with high mortality. Etoposide–dexamethasone (ED)-based therapy is standard of care, but patients with ED-refractory disease have no approved salvage options. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a key regulator of inflammatory signaling and necroptosis; ORIC-1940 is a highly selective, small-molecule RIPK1 inhibitor that demonstrated anti-inflammatory and organ-protective activity in preclinical HLH animal models. We report safety and efficacy results from a Phase 1b study of ORIC-1940 combined with ED in adults with protocol-defined ED-refractory EBV- or lymphoma-associated HLH.

 

Methods: ORIC-1940-HLH-Ib01 is a multicenter, open-label Phase 1b dose-exploration and expansion study. Adult refractory HLH were eligible. The dose-exploration phase planned to enroll up to 10 patients using a 2-stage design. Intravenous ORIC-1940 was started at 160 mg/day, with escalation to 240 mg/day permitted after integrated review of safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy. Patients received 14 days of treatment and, if deriving clinical benefit, could continue maintenance therapy for up to 8 weeks; during maintenance, the dose could be reduced to 80 mg/day. Based on completed dose exploration, 240 mg/day was selected for the expansion phase, with total planned enrollment capped at 40 patients. The primary endpoints are safety and overall response rate (ORR; complete response + partial response) at day 15.  Secondary endpoints include best response, time to response, duration of response, all-cause mortality, cumulative etoposide exposure.

 

Results: As of the data cutoff, 8 patients with refractory HLH (EBV-associated, n=4; lymphoma-associated, n=3; and lymphoma with concurrent EBV infection, n=1) were enrolled and received ORIC-1940 120 mg twice daily in combination with ED (E 100mg twice weekly, D 10mg once daily). All patients had previously received HLH-directed regimens, including 6 who received ED and 2 who received ED plus ruxolitinib. Among the 6 patients who completed 14-day study regimen, no treatment-related Grade ≥3 adverse events or dose-limiting toxicities occurred. Two patients died from complications unrelated to study treatment before the Day 15 evaluation: one from gastrointestinal bleeding in the setting of progressive NK/T-cell lymphoma, and another from sepsis caused by multidrug-resistant organisms (Klebsiella pneumoniae and Pseudomonas aeruginosa).

 

Among the six patients with complete paired baseline–Day 15 samples, clinically meaningful improvements were observed across multiple HLH parameters. The overall response rate was 100% with all responders achieving partial remission (PR). Changes of the laboratory indicators were most pronounced for soluble CD25 (median –57.0%; four of five patients achieved >50% reduction) and fibrinogen (median –56.3%; five of six patients improved). Ferritin declined by a median of –27.6%, with two-thirds of patients showing improvement, while triglycerides (–16.5%) and hemoglobin (–19.7%) changed more modestly. Platelet counts rose markedly (median +198.4%), with four of six patients exceeding a 50% increase. In terms of rapidity of response, fibrinogen (median 5.5 days) and platelets (4.5 days) improved earliest. Ferritin and soluble CD25 required a median of 11 days to achieve a ≥50% decline.

 

Conclusions: ORIC-1940 added to ED demonstrated a manageable safety profile and early signals of clinical activity in adults with ED-refractory EBV- or lymphoma-associated HLH. Rapid declines in ferritin and soluble CD25, accompanied by improvements in platelet counts and fibrinogen levels, were observed in most evaluable patients. These findings support further evaluation of this combination strategy in this difficult-to-treat population.

Ting Niu: No relevant conflicts of interest to declare.